Published in Dev Neurosci on January 01, 1994
Role of microglia in central nervous system infections. Clin Microbiol Rev (2004) 2.69
Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J Neurosci (2006) 1.90
Ligation of CD40 stimulates the induction of nitric-oxide synthase in microglial cells. J Biol Chem (2001) 1.71
Induction of nitric-oxide synthase and activation of NF-kappaB by interleukin-12 p40 in microglial cells. J Biol Chem (2000) 1.70
Up-regulation of microglial CD11b expression by nitric oxide. J Biol Chem (2006) 1.64
Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol (2001) 1.58
Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neuroimmune Pharmacol (2014) 1.57
Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol (2007) 1.35
The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro (2011) 1.19
Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis. J Biol Chem (2002) 1.16
Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis (2001) 1.16
Microglia in Alzheimer's disease and transgenic models. How close the fit? Am J Pathol (1999) 1.09
Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. Glia (2011) 1.06
Toll-like receptor expression and activation in astroglia: differential regulation by HIV-1 Tat, gp120, and morphine. Immunol Invest (2011) 1.04
STAT6⁻/⁻ mice exhibit decreased cells with alternatively activated macrophage phenotypes and enhanced disease severity in murine neurocysticercosis. J Neuroimmunol (2010) 1.02
Upregulation of RANTES gene expression in neuroglia by Japanese encephalitis virus infection. J Virol (2004) 1.00
Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. Clin Diagn Lab Immunol (1998) 0.98
Diminished cytokine and chemokine expression in the central nervous system of GMF-deficient mice with experimental autoimmune encephalomyelitis. Brain Res (2007) 0.97
IL-12 p40 homodimer, the so-called biologically inactive molecule, induces nitric oxide synthase in microglia via IL-12R beta 1. Glia (2009) 0.94
Implications of glial nitric oxide in neurodegenerative diseases. Front Cell Neurosci (2015) 0.93
Aberrant expression of interleukin-1β and inflammasome activation in human malignant gliomas. PLoS One (2014) 0.90
Inhibition of reactive gliosis prevents neovascular growth in the mouse model of oxygen-induced retinopathy. PLoS One (2011) 0.89
Comparison of inducible nitric oxide synthase expression in the brains of Listeria monocytogenes-infected cattle, sheep, and goats and in macrophages stimulated in vitro. Infect Immun (1997) 0.85
The Role of Astrocytes in Multiple Sclerosis Progression. Front Neurol (2015) 0.84
Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell cultures. J Neuroinflammation (2009) 0.83
Astrocytic metabolic and inflammatory changes as a function of age. Aging Cell (2014) 0.83
Phosphatidylinositol 3-kinase/protein kinase Cdelta activation induces close homolog of adhesion molecule L1 (CHL1) expression in cultured astrocytes. Glia (2010) 0.81
Production, regulation and role of nitric oxide in glial cells. Mediators Inflamm (1998) 0.77
PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption. Oncotarget (2015) 0.77
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med (2001) 4.35
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain (2007) 3.82
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol (1988) 3.63
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology (2006) 3.60
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
A neuronal antigen in the brains of Alzheimer patients. Science (1986) 3.49
Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun (1995) 3.43
Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun (2000) 3.42
Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology (2004) 3.41
Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol (1999) 3.38
Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A (2001) 3.37
Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol (2001) 3.34
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet (1993) 3.34
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med (2000) 3.20
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science (1994) 3.00
Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science (1983) 2.91
Observations on viral demyelinating encephalomyelitis. Canine distemper. Lab Invest (1972) 2.88
Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis (1994) 2.87
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol (1975) 2.86
Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology (1999) 2.81
Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol (1991) 2.80
Molecular cloning of a transcription factor, AGP/EBP, that belongs to members of the C/EBP family. Mol Cell Biol (1990) 2.78
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med (1994) 2.70
MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology (2008) 2.69
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol (1995) 2.57
Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia (1993) 2.51
Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med (1997) 2.51
Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol (1993) 2.46
Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology (2008) 2.45
Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol (1994) 2.43
Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun (1994) 2.41
Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics (2001) 2.40
Late complications of immune deviation therapy in a nonhuman primate. Science (1996) 2.30
Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. Nature (1988) 2.27
Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol (2001) 2.27
Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol (1997) 2.25
Cockayne syndrome and xeroderma pigmentosum. Neurology (2000) 2.24
Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J Clin Microbiol (1997) 2.19
Intercostal arteriovenous fistula due to pleural biopsy. Thorax (1990) 2.15
Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans. Infect Immun (1996) 2.15
Electron microscopic observations on the cerebellar cortex in kuru. J Neurol Sci (1969) 2.14
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology (2004) 2.12
Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun (1998) 2.12
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology (2001) 2.08
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem (1996) 2.05
Risk factors for epistaxis during nasotracheal intubation. Anaesth Intensive Care (2002) 2.04
Homing to central nervous system vasculature by antigen-specific lymphocytes. I. Localization of 14C-labeled cells during acute, chronic, and relapsing experimental allergic encephalomyelitis. Lab Invest (1990) 2.03
Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology (2008) 2.01
Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest (1991) 2.01
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother (1994) 2.00
Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci (1997) 2.00
Pathology and biology of the Lewy body. J Neuropathol Exp Neurol (1993) 1.99
Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology (2003) 1.97
Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. Proc Natl Acad Sci U S A (1987) 1.96
Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature (1984) 1.95
Senile plaques and cerebral amyloidosis in aged dogs. A histochemical and ultrastructural study. Lab Invest (1970) 1.93
TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology (2010) 1.93
GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron (1996) 1.91
Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann Neurol (1995) 1.91
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother (1997) 1.89
Medulloblastoma with glial and rhabdomyoblastic differentiation. A myoglobin and glial fibrillary acidic protein immunohistochemical and ultrastructural study. J Neuropathol Exp Neurol (1983) 1.88
Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology (2004) 1.86
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A (1993) 1.86
A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience (2007) 1.86
Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol (1991) 1.84
Monoclonal antibodies to Alzheimer neurofibrillary tangles. 1. Identification of polypeptides. Am J Pathol (1985) 1.84
Role of streptococcal pyrogenic exotoxin B in the mouse model of group A streptococcal infection. Infect Immun (1998) 1.84
The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest (1993) 1.84
Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest (1984) 1.83
Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun (1994) 1.83
Attentional biases for negative information in induced and naturally occurring dysphoria. Behav Res Ther (1997) 1.83
Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev (1998) 1.82
Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology (2006) 1.81
Cytochrome c folding triggered by electron transfer. Chem Biol (1996) 1.80
Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol (2000) 1.79
Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol (1998) 1.79
Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun (1995) 1.79
Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immun (2000) 1.79